NATICK, Mass., Feb. 12 /PRNewswire-FirstCall/ -- Boston Scientific
Corporation (NYSE: BSX) today announced that a U.S. District Court jury in
Marshall, Texas has reached a verdict in a patent infringement suit brought
against the Company by Dr. Bruce Saffran. The jury found that the Company's
TAXUS® Express® and TAXUS® Liberte™ drug-eluting stent products
infringe Dr. Saffran's patent and that the patent is valid. No injunction was
requested, but the jury awarded damages of $431 million.
The Company believes the jury verdict is unsupported by both the evidence
and the law. On these grounds, the Company plans to seek to overturn the
verdict in post-trial motions before the District Court and, if unsuccessful,
to appeal to the U.S. Court of Appeals for the Federal Circuit. The Company
believes it will prevail on appeal.
Boston Scientific is a worldwide developer, manufacturer and marketer of
medical devices whose products are used in a broad range of interventional
medical specialties. For more information, please visit:
www.bostonscientific.com.
Cautionary Statement Regarding Forward Looking Statements
This press release contains forward-looking statements within the meaning
of Section 21E of the Securities Exchange Act of 1934. Forward-looking
statements may be identified by words like "anticipate," "expect," "project,"
"believe," "plan," "estimate," "intend" and similar words. These forward-
looking statements are based on our beliefs, assumptions and estimates using
information available to us at the time and are not intended to be guarantees
of future events or performance. These forward-looking statements include,
among other things, statements regarding intellectual property litigation and
competitive offerings. If our underlying assumptions turn out to be
incorrect, or if certain risks or uncertainties materialize, actual results
could vary materially from the expectations and projections expressed or
implied by our forward-looking statements. These factors, in some cases, have
affected and in the future (together with other factors) could affect our
ability to implement our business strategy and may cause actual results to
differ materially from those contemplated by the statements expressed in this
press release. As a result, readers are cautioned not to place undue reliance
on any of our forward-looking statements.
Factors that may cause such differences include, among other things:
future economic, competitive, reimbursement and regulatory conditions; new
product introductions; demographic trends; intellectual property; litigation;
financial market conditions; and, future business decisions made by us and our
competitors. All of these factors are difficult or impossible to predict
accurately and many of them are beyond our control. For a further list and
description of these and other important risks and uncertainties that may
affect our future operations, see Part I, Item 1A- Risk Factors in our most
recent Annual Report on Form 10-K filed with the Securities and Exchange
Commission, which we may update in Part II, Item 1A - Risk Factors in
Quarterly Reports on Form 10-Q we have filed or will file thereafter. We
disclaim any intention or obligation to publicly update or revise any forward-
looking statements to reflect any change in our expectations or in events,
conditions, or circumstances on which those expectations may be based, or that
may affect the likelihood that actual results will differ from those contained
in the forward-looking statements. This cautionary statement is applicable to
all forward-looking statements contained in this document.
CONTACT:
Paul Donovan
508-650-8541 (office)
508-667-5165 (mobile)
Media Relations
Boston Scientific Corporation
Larry Neumann
508-650-8696 (office)
Investor Relations
Boston Scientific Corporation
